Overview

Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

Status:
Recruiting
Trial end date:
2020-08-27
Target enrollment:
Participant gender:
Summary
This study is to evaluate the bioequivalence of Oseltamivir Phosphate Capsules 75 mg versus TAMIFLU 75 mg capsules administered as 75 mg capsules in healthy volunteers under Fed condition.
Phase:
Phase 1
Details
Lead Sponsor:
Austarpharma, LLC
Treatments:
Oseltamivir